Voya Investment Management LLC Reduces Holdings in ADMA Biologics Inc $ADMA

Key Points

• Voya Investment Management LLC has reduced its holdings in ADMA Biologics Inc by 4.8% in Q1, now owning 874,603 shares valued at approximately $17.35 million after selling 43,758 shares.
• During the same period, other large investors like Invesco Ltd. and Driehaus Capital Management LLC increased their stakes significantly, indicating strong institutional interest in ADMA Biologics.
• ADMA Biologics reported earnings of $0.15 per share, beating estimates, with revenues reaching $121.98 million, representing a 13.8% increase year-over-year.

Voya Investment Management LLC decreased its position in ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 4.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 874,603 shares of the biotechnology company's stock after selling 43,758 shares during the period. Voya Investment Management LLC owned 0.37% of ADMA Biologics worth $17,352,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the stock. Invesco Ltd. lifted its holdings in shares of ADMA Biologics by 13.9% in the 1st quarter. Invesco Ltd. now owns 12,866,904 shares of the biotechnology company's stock worth $255,279,000 after acquiring an additional 1,570,649 shares during the last quarter. Nuveen LLC acquired a new stake in ADMA Biologics during the 1st quarter worth approximately $93,543,000. American Century Companies Inc. lifted its holdings in ADMA Biologics by 12.7% during the 1st quarter. American Century Companies Inc. now owns 4,252,362 shares of the biotechnology company's stock worth $84,367,000 after buying an additional 478,800 shares in the last quarter. Allspring Global Investments Holdings LLC raised its holdings in shares of ADMA Biologics by 7.3% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 3,048,946 shares of the biotechnology company's stock valued at $59,211,000 after purchasing an additional 207,097 shares in the last quarter. Finally, Driehaus Capital Management LLC raised its holdings in shares of ADMA Biologics by 114.9% in the 1st quarter. Driehaus Capital Management LLC now owns 2,946,570 shares of the biotechnology company's stock valued at $58,460,000 after purchasing an additional 1,575,363 shares in the last quarter. 75.68% of the stock is currently owned by institutional investors and hedge funds.

ADMA Biologics Price Performance

Shares of NASDAQ:ADMA opened at $15.30 on Tuesday. The company's fifty day moving average price is $17.42 and its 200 day moving average price is $18.98. ADMA Biologics Inc has a 12 month low of $13.50 and a 12 month high of $25.67. The company has a debt-to-equity ratio of 0.21, a current ratio of 5.33 and a quick ratio of 2.78. The firm has a market capitalization of $3.65 billion, a P/E ratio of 17.79 and a beta of 0.54.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported $0.15 EPS for the quarter, topping the consensus estimate of $0.14 by $0.01. ADMA Biologics had a net margin of 44.06% and a return on equity of 41.01%. The firm had revenue of $121.98 million for the quarter, compared to analyst estimates of $121.77 million. During the same period last year, the business earned $0.13 EPS. ADMA Biologics's revenue for the quarter was up 13.8% compared to the same quarter last year. As a group, sell-side analysts predict that ADMA Biologics Inc will post 0.51 earnings per share for the current fiscal year.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.